MarketsandMarkets projects a 25.3% compound annual growth rate (CAGR) driven by induced pluripotent stem cell (iPSC) advances, dominance of patient derived (autologous) therapies, and expanding regenerative medicine investment—but Europe's outlier 48.3% growth rate warrants…
A new market analysis projects the global stem cell therapy market will expand from roughly $480 million in 2026 to $3.65 billion by 2035, a nearly eight-fold jump that reflects accelerating investment in regenerative medicine, advances in induced pluripotent stem cell (iPSC) technologies, and a broadening pipeline of clinical-stage cell therapies.
According to MarketsandMarkets, the market is expected to grow at a compound annual growth rate of 25.3% over the forecast period (2026–2035). The growth is driven by increasing prevalence of chronic and degenerative diseases, rising investments in regenerative medicine, and expanding clinical trial activity for stem cell-based therapies.
The report identifies several structural tailwinds fueling the sector's expansion. Technological advancements in cell sourcing, stem cell isolation, ex vivo expansion, closed-system manufacturing, automated cell processing, cryopreservation, potency testing, and high-throughput quality control workflows are making stem cell therapy development and manufacturing more scalable, reproducible, and commercially reliable.
"These advancements are particularly important for autologous therapies, where patient-specific variability and chain-of-identity control are critical, and for allogeneic therapies, where consistent donor-cell expansion, batch-to-batch comparability, and long-term cell viability are essential for off-the-shelf product supply," the report notes.
Evolving GMP requirements, CMC expectations, donor eligibility standards, sterility controls, potency assay requirements, traceability systems, and post-market safety monitoring frameworks are also pushing developers and manufacturers to adopt validated, closed, and contamination-controlled manufacturing platforms.
Within the broader market, the induced pluripotent stem cells (iPSC) segment is projected to grow at the highest CAGR between 2026 and 2035, reflecting the technology's versatility and potential for personalized cell therapies.
The autologous stem cell therapy segment accounted for the largest market share in 2025, while the musculoskeletal disorders segment held the largest share by therapeutic application in the same year.
Europe is identified as the fastest-growing regional segment, with a projected CAGR of 48.3% in the global stem cell therapy market—a figure that substantially outpaces the global average and warrants independent corroboration before use in published reporting.
The projections come from MarketsandMarkets, a commercial research firm that publishes market reports available for purchase. As with all market-sizing estimates from commercial research providers, the figures reflect a particular methodology, definitional scope, and assumptions about market boundaries. The 25.3% global CAGR figure and the Europe-specific 48.3% CAGR should be treated as directional indicators from a single source rather than independently verified benchmarks.
The analysis is released on June 15, 2026, and represents a current snapshot of market expectations as of that date.